The current therapeutic guidelines recommend neoadjuvant treatment with single HER2-targeted therapy of trastuzumab or dual HER2-targeted therapy of trastuzumab and pertuzumab for HER2-positive breast cancer patients in early/locally advanced/inflammatory stages with any tumour sized ≥ 2 cm or with nodal positivity. Here, ERBB2 is linked to breast carcinoma.